SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

With reference to the news article in The Economic Times, on July 22, 2015 captioned ‘Aurobindo Pharma Comes Under US FDA Lens’, Aurobindo Pharma has Clarified that the said facility underwent a routine GMP inspection by USFDA and there are certain observations related to the systems and procedures. The Company is appropriately responding and this has no perceived impact on the operations and exports from the said facility.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1371.80 -13.85 (-1.00%)
20-Apr-2026 12:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.35
Dr. Reddys Lab 1236.85
Cipla 1232.80
Zydus Lifesciences 942.40
Lupin 2332.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×